Gossamer Bio FY2025 EPS Estimate Raised by Cantor Fitzgerald

Gossamer Bio, Inc. (NASDAQ:GOSS) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now expects that the company will earn ($0.70) per share for the year, up from their prior estimate of ($0.72). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million.

Other analysts also recently issued reports about the company. Wedbush reaffirmed an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Tuesday, March 18th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Gossamer Bio has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $1.18 on Wednesday. The company has a market cap of $268.12 million, a P/E ratio of -3.69 and a beta of 1.86. The firm has a fifty day moving average price of $1.19 and a 200 day moving average price of $0.99. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GOSS. Octagon Capital Advisors LP grew its position in shares of Gossamer Bio by 99.7% during the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock worth $16,599,000 after acquiring an additional 9,162,117 shares during the last quarter. Alyeska Investment Group L.P. grew its position in Gossamer Bio by 52.7% during the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after purchasing an additional 3,041,058 shares during the last quarter. Silverarc Capital Management LLC increased its stake in Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after purchasing an additional 526,495 shares during the period. Monaco Asset Management SAM raised its holdings in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after buying an additional 1,520,721 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Gossamer Bio by 14.6% during the fourth quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock worth $3,244,000 after buying an additional 457,179 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.